Login / Signup

High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.

Nicole PfarrKarin von SchwarzenbergDario ZochollSabine Merkelbach-BruseJanna SiemanowskiEva-Maria MayrSylvia HeroldKarsten KleoLukas C HeukampEva Maria WillingMichael MenzelUlrich LehmannStephan BartelsShounak ChakrabortyGustavo BarettonMelanie C DemesClaudia DöringDaniel N KazdalJan BudcziesRoland RadPeter WildYann ChristinatThomas A McKeePeter SchirmacherDavid HorstReinhard ButtnerAlbrecht StenzingerJalid SehouliClaudia VollbrechtMichael HummelElena I BraicuWilko Weichertnull null
Published in: JCO precision oncology (2024)
Assays for GI assessment not only show a high concordance with each other but also in correlation with Myriad myChoice. Thus, almost all of the assays included here can be used effectively to assess HRD-associated GI in the clinical setting. This is important as PARPi treatment on the basis of these tests is compliant with European Medicines Agency approvals, which are methodologically not test-bound.
Keyphrases
  • high throughput
  • dna repair
  • dna damage
  • replacement therapy
  • copy number
  • gene expression
  • solid phase extraction
  • mass spectrometry
  • oxidative stress
  • combination therapy
  • molecularly imprinted